ArticleBritish journal of cancer2023

The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study.

Hsiang-Lin Tsai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.